On Novemeber 23, 2021, the U.S. Food and Drug Administration (FDA) approved sirolimus protein-bound particles for injectable suspension (albumin-bound) for intravenous use for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).
Read Aadi Bioscience, Inc.'s announcement.
Posted 11/23/2021
An at-home option for cervical cancer screening breaks down barriers to care and offers the same level of precision as screening in the clinic.
